https://orcid.org/0000-0002-5753-7824
References
- Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–1531.
- Foà R, Bassan R, Vitale A, et al. Dasatinib-Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–1623.
- Chen J, Ngo D, Rosenthal J. Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with Central nervous system disease. J Oncol Pharm Pract. 2019;25(8):2027–2030.
- Alfayez M, Kantarjian HM, Short NJ, et al. Safety and efficacy of blinatumomab in patients with Central nervous system (CNS) disease: a single institution experience. Blood. 2018;132(Supplement 1):2702–2702.
- Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–2498.
- Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–4140.
- Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
- Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
- Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-Precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, Single-Arm, multicenter study. J Clin Oncol. 2017;35(16):1795–1802.
- Parker KR, Migliorini D, Perkey E, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126–142.e17.
- Stein AS, Schiller G, Benjamin R, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98(1):159–167.
- Peyriere H, Poiree M, Cociglio M, et al. Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Med Pediatr Oncol. 2001;36(6):662–664.
- Razi W, Haque AU, Sadiq H, et al. Safety and efficacy of aminophylline in intrathecal methotrexate-related neurological toxicity in large pediatric oncology Centre. J Coll Physicians Surg Pak. 2021;30(4):481–484.
- Cohen IJ, Stark B, Kaplinsky C, et al. Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature. Pediatr Hematol Oncol. 1990;7(1):79–87.
- Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet. 1995;345(8949):544–547.
- Rubin MF, Kuhn AK. Management of methotrexate-induced neurotoxicity with aminophylline plus dextromethorphan in a pediatric patient with pineoblastoma. Pediatr Blood Cancer. 2020;67(12):e28515.
- Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate Central nervous system toxicity. Pediatr Neurol. 2014;50(6):625–629.
- Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol. 2002;19(5):319–327.
- Coker SA, Pastel DA, Davis MC, et al. Methotrexate encephalopathy: two cases in adult cancer patients, who recovered with pathophysiologically based therapy. SAGE Open Med Case Rep. 2017;5:2050313X17706875.